

CITATION REPORT

List of articles citing

Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications

DOI: 10.1016/j.clinthera.2013.04.004
Clinical Therapeutics, 2013, 35, 808-18.

Source: <https://exaly.com/paper-pdf/55151140/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	Antihelminthic niclosamide modulates dendritic cells activation and function. <i>Cellular Immunology</i> , 2014 , 288, 15-23	4.4	14
26	The pediatric studies initiative: after 15 years have we reached the limits of the law?. <i>Clinical Therapeutics</i> , 2014 , 36, 156-62	3.5	17
25	Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. <i>BMJ, The</i> , 2015 , 351, h4679	5.9	21
24	Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2015 , 20, 186-96	1.6	23
23	In vitro screening for drug repositioning. <i>Journal of Biomolecular Screening</i> , 2015 , 20, 167-79		37
22	Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. <i>PLoS ONE</i> , 2016 , 11, e0152195	3.7	2
21	Making Up Is Hard to Do: Knowledge Acquisition Strategies and the Nature of New Product Innovation. <i>Journal of Product Innovation Management</i> , 2016 , 33, 472-491	7.1	27
20	Small Molecules in Development for the Treatment of Spinal Muscular Atrophy. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 10067-10083	8.3	46
19	Competitive Development in Pharmacologic Classes: Market Entry and the Timing of Development. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 754-760	6.1	6
18	Success rates for product development strategies in new drug development. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 198-202	2.2	5
17	Extensions of indication throughout the drug product lifecycle: a quantitative analysis. <i>Drug Discovery Today</i> , 2016 , 21, 348-55	8.8	13
16	How excluding some benefits from value assessment of new drugs impacts innovation. <i>Health Economics (United Kingdom)</i> , 2017 , 26, 1813-1825	2.4	1
15	Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval. <i>Milbank Quarterly</i> , 2017 , 95, 261-290	3.9	39
14	Drug Regulation and Oversight, from Local to Global. <i>Journal of Pharmaceutical Innovation</i> , 2017 , 12, 185-187	1.8	1
13	Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. <i>Blood Cancer Journal</i> , 2017 , 7, 637	7	3
12	Drug Repurposing Review. 2017 , 11-47		4
11	Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. <i>MABs</i> , 2020 , 12, 1787121	6.6	9

10	FDA review times for new drugs in ophthalmology. <i>Ocular Surface</i> , 2020 , 18, 963-966	6.5	2
9	Microphysiological Systems: A Pathologist's Perspective. <i>Veterinary Pathology</i> , 2020 , 57, 358-368	2.8	3
8	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020 , 395, 998-1010	10	23
7	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018. <i>Clinical Trials</i> , 2021 , 18, 488-499	2.2	7
6	Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 684515	5.9	7
5	U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.		1
4	How Excluding Some Benefits from Value Assessment of New Medicines Impacts Innovation. <i>SSRN Electronic Journal</i> ,	1	
3	The Effect of Cigarette Smoke Exposure on Efferocytosis in Chronic Obstructive Pulmonary Disease; Molecular Mechanisms and Treatment Opportunities. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-14	2	1
2	Charted Territory: Evidence from Mapping the Cancer Genome and R&D Decisions in the Pharmaceutical Industry. <i>SSRN Electronic Journal</i> ,	1	
1	Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.		3